Aspartate transaminase

Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

Retrieved on: 
Monday, May 9, 2022
People, Aspartate transaminase, Interim, QT interval, Osteogenesis imperfecta, ULN, Biomarker, Safety, Cystic fibrosis, Șaeș, Degenerative disease, Cough, Atalanta, Annual report, Death, Respiratory disease, Bronchiectasis, Respiratory tract, Standard of care, Forward-looking statement, Headache, AES, AATD, Bilirubin, Company, FEV1, Plasma, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, AST, Patient, Infection, COPD, Fibrosis, Desmosine, Ovarian cancer, CF, AAT, U.S. Securities and Exchange Commission, LSM, Neoplasm, Interest group, Security (finance), Adverse Events, Form 6-K, COVID-19, Arm, BOS, Monaco Age Oncologie, Therapy, History, OI, AE, Medical imaging, Pharmaceutical industry, Alanine transaminase, AstraZeneca

LONDON and REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase 2 study of the investigational oral neutrophil elastase (NE) inhibitor, alvelestat (MPH-966), in patients with severe alpha-1 antitrypsin deficiency-associated emphysema.

Key Points: 
  • Consistent with the known safety profile of alvelestat, no safety signals were observed in adverse event (AE) monitoring.
  • Most AEs were mild to moderate, including within Adverse Events of Special Interest (AESI) which were observed in 23 subjects.
  • Prior to Mereo BioPharma licensing alvelestat from AstraZeneca (AZ), trials across COPD, bronchiectasis and cystic fibrosis (CF) had been performed.
  • Mereo reported a positive Phase 1b/2 trial in COVID-19 which was completed in 2021 and showed alvelestat was safe and well tolerated.

Outlook on the Medical Enzyme Technology Global Market to 2028 - Rising Production of Biopharmaceutical Products Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, Medical specialties, Biology, Medical genetics, Metabolism, Pancreas disorders, Abdominal pain, Pancreatitis, Jaundice, Metabolic disorder, Aspartate transaminase, Neurodegeneration

Abnormalities in enzyme metabolism system leads to many metabolic diseases.

Key Points: 
  • Abnormalities in enzyme metabolism system leads to many metabolic diseases.
  • Many enzymes are being widely used in the clinical examination as a specific disease marker.
  • Enzymes are the preferred markers in various disease states such as myocardial infarction, jaundice, pancreatitis, cancer, and neurodegenerative disorders.
  • However, the market for normothermic machine perfusion is estimated to grow at a higher CAGR of 4.4% during the forecast period.\nThe medical enzyme technology market, by application, is segmented into disease treatment, diagnostic tools, biomedical research, and others.

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare Clinical Study on CBD Liver Toxicity

Retrieved on: 
Tuesday, March 23, 2021
Liver function tests, Hepatology, Branches of biology, Clinical medicine, Glutamate, Medicine, Alanine transaminase, Biomarkers, Enzymes, Bilirubin, Aspartate transaminase, Alkaline phosphatase

Blood markers for ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), ALP (Alkaline Phosphatase), and Bilirubin levels were examined during the study.

Key Points: 
  • Blood markers for ALT (Alanine Aminotransferase), AST (Aspartate Aminotransferase), ALP (Alkaline Phosphatase), and Bilirubin levels were examined during the study.
  • These study results help support the work that weve been doing in Mexico and Brazil to study CBDs safety and efficacy, said Medical Marijuana, Inc. CEO Dr. Stuart Titus.
  • Brands that participated in this study provided funding, product, certificates of authenticity, and assisted with the recruitment of adult US-based consumers.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

LGC Maine Standards announces VALIDATE® IL-6 kit for Roche cobas® with Interleukin-6 for easy, fast, and reliable documentation of linearity, calibration verification, and Analytical Measurement Range (AMR) verification.

Retrieved on: 
Tuesday, December 22, 2020
Chemical pathology, Muscular system, Troponin, Glutamate, Liver function tests, Creatine kinase, Aspartate transaminase

CUMBERLAND FORESIDE, Maine, Dec. 22, 2020 /PRNewswire/ --LGC Maine Standards announces the release of VALIDATE IL-6 to meet the linearity and calibration verification needs of clinical laboratories running the Roche cobas platform.

Key Points: 
  • CUMBERLAND FORESIDE, Maine, Dec. 22, 2020 /PRNewswire/ --LGC Maine Standards announces the release of VALIDATE IL-6 to meet the linearity and calibration verification needs of clinical laboratories running the Roche cobas platform.
  • 403RO), Troponin I and Troponin T in VALIDATE CM2 (402RE), and Creatine Kinase and Aspartate Aminotransferase in VALIDATE GC3 (Order No.
  • VALIDATE products allow clinical laboratories to complete their required linearity and calibration verification, maximizing the reportable range while minimizing manual dilutions.
  • LGC Maine Standards is the brand name for Maine Standards Company, LLC, and an entity of LGC Clinical Diagnostics Division.

AST & Science LLC to Become Public Company Through Combination with New Providence Acquisition Corp. (NASDAQ: NPA, NPAUU and NPAWW)

Retrieved on: 
Wednesday, December 16, 2020
Aspartate transaminase, Glutamate, Augstsprieguma tīkls, Avellan

Abel Avellan, Chairman and Chief Executive Officer of AST SpaceMobile, will continue to lead the business post-transaction.

Key Points: 
  • Abel Avellan, Chairman and Chief Executive Officer of AST SpaceMobile, will continue to lead the business post-transaction.
  • AST SpaceMobile and New Providence have secured a commitment for a $230 million private placement investment ("PIPE") to be consummated at the closing of the transaction.
  • "Facing an extraordinary market opportunity, we believe AST SpaceMobile is poised for sustained growth as it executes its commercialization plan and ultimate expansion across the globe."
  • The cash proceeds are expected to be used to fund phase one of the commercial launch of AST SpaceMobile's space assets.

Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

Retrieved on: 
Saturday, December 5, 2020
Medical specialties, Liver function tests, Clinical medicine, Glutamate, Medicine, Immunology, Alanine transaminase, Enzymes, Hepatology, Aspartate transaminase, Antibody, Bispecific monoclonal antibody

Dose-limiting toxicity was reported in 2 patients with 1 patient experiencing acute kidney injury and 1 patient experiencing elevated alanine aminotransferase (ALT)/raised aspartate aminotransferase (AST).

Key Points: 
  • Dose-limiting toxicity was reported in 2 patients with 1 patient experiencing acute kidney injury and 1 patient experiencing elevated alanine aminotransferase (ALT)/raised aspartate aminotransferase (AST).
  • "REGN5458 is the second CD3 bispecific in our oncology portfolio to show clinically meaningful results.
  • We are currently enrolling patients in a potentially registrational Phase 2 portion of this REGN5458 trial.
  • These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease

Retrieved on: 
Friday, November 13, 2020
Pharmaceutical, Genetics, Health, Clinical trials, Liver, Medical specialties, Hepatology, Glutamate, Liver function tests, Clinical medicine, American Association for the Study of Liver Diseases, Liver disease, Aspartate transaminase, Alanine transaminase, Elastography

The data demonstrate that three doses of ARO-AAT over 24-weeks resulted in consistent reductions of the disease-causing mutant Z protein (Z-AAT) and improvements in clinically relevant biomarkers of liver disease.

Key Points: 
  • The data demonstrate that three doses of ARO-AAT over 24-weeks resulted in consistent reductions of the disease-causing mutant Z protein (Z-AAT) and improvements in clinically relevant biomarkers of liver disease.
  • The results were presented in a late-breaking poster at The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
  • Importantly, we saw reductions in serum Z-AAT and liver Z-AAT which led to improvements in multiple markers, such as liver globules, ALT/GGT and Pro-C3.
  • Assessments included safety (including pulmonary function tests), changes in serum Z-AAT, liver Z-AAT, ALT, GGT, Pro-C3, liver elastography (FibroScan), and liver globule assessment.

Echosens Engages Santa Barbara Actuaries to Demonstrate Cost-effectiveness of FibroScan Non-invasive Technology for Measuring Liver Fat and Stiffness, Answers Payer Needs to Address NAFLD and NASH Epidemic

Retrieved on: 
Tuesday, March 24, 2020
General Health, Health, Other Health, Medical devices, Liver, Medicine, Medical specialties, Liver function tests, Glutamate, Federal assistance in the United States, Healthcare reform in the United States, Presidency of Lyndon B. Johnson, Non-alcoholic fatty liver disease, Elastography, Aspartate transaminase, Medicare

FibroScan provides a non-invasive, rapid and painless examination that is covered under commercial, Medicare and Medicaid, empowering healthcare providers with an accurate tool to measure liver fat and stiffness.

Key Points: 
  • FibroScan provides a non-invasive, rapid and painless examination that is covered under commercial, Medicare and Medicaid, empowering healthcare providers with an accurate tool to measure liver fat and stiffness.
  • As the newest enhancement to FibroScan, FibroScan-AST (FAST) Score combines the fat and stiffness values from the FibroScan exam with aspartate aminotransferase (AST), a marker of inflammation.
  • It is expected that over the next few years, the pharmaceutical treatment market for NAFLD and NASH could potentially reach $35 billion .
  • FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.

Global and Chinese Market Glutamic Pyruvic Transaminase (GPT) Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2019
Biotechnology, Manufacturing, Health, Chemicals, Plastics, Enzymes, Carboxylic acids, Glutamate, Hepatology, Transaminase, Transferases, Flavor enhancers, GPT, Aspartate transaminase, Glutamic acid, GPT2

The "Glutamic Pyruvic Transaminase (GPT) Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glutamic Pyruvic Transaminase (GPT) Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Glutamic Pyruvic Transaminase (GPT) Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Glutamic Pyruvic Transaminase (GPT) industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Glutamic Pyruvic Transaminase (GPT) market covering all important parameters.
  • 5.2 Market Competition of Glutamic Pyruvic Transaminase (GPT) Industry by Country (USA, EU, Japan, Chinese etc.)

Axcella to Present at the Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 7, 2019
Biotechnology, Pharmaceutical, Health, Aspartate transaminase, Glutamate

A live webcast of the presentation will be available on the Investors & News section of Axcellas website at https://ir.axcellahealth.com.

Key Points: 
  • A live webcast of the presentation will be available on the Investors & News section of Axcellas website at https://ir.axcellahealth.com.
  • A replay of the webcast will be archived on Axcellas website for 90 days following the presentation.
  • Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health.
  • Axcellas AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood.